Luye Pharma Group Ltd.

Symbol: 2186.HK

HKSE

3.02

HKD

Market price today

  • 19.5312

    P/E Ratio

  • 1.7954

    PEG Ratio

  • 11.36B

    MRK Cap

  • 0.00%

    DIV Yield

Luye Pharma Group Ltd. (2186-HK) Stock Price & Analysis

Shares Outstanding

0M

Gross Profit Margin

0.68%

Operating Profit Margin

0.14%

Net Profit Margin

0.09%

Return on Assets

0.02%

Return on Equity

0.04%

Return on Capital Employed

0.05%

Company general description and statistics

Sector: Healthcare
Industry: Drug Manufacturers - General
CEO:Mr. Dian Bo Liu
Full-time employees:5005
City:Yantai
Address:No. 15 Chuang Ye Road
IPO:2014-07-09
CIK:

Luye Pharma Group Ltd., an investment holding company, develops, produces, markets, and sells pharmaceutical products worldwide. The company offers Lipusu for ovarian and breast cancer; CMNa, a chemical sensitizer for cancer radiotherapy; Tiandida for ovarian or non-small cell lung cancer; Boyounuo, an injection for the treatment of various types of cancers and other solid tumors; and Xuezhikang, a lipid regulating drug for the treatment of hypercholesterolaemia. It also provides Maitongna for cerebral edema swelling by trauma or surgery, and for venous reflux disorders; Beixi, an acarbose capsule for Type 2 diabetes; Rivastigmine Transdermal Patch for the treatment of Alzheimer's disease; Fentanyl Transdermal Patch for cancer pain; Buprenorphine Transdermal Patch for chronic pain; and Seroquel and Seroquel XR for the treatment of schizophrenia and manic episodes of bipolar affective disorders, In addition, the company offers Rykindo, an injection for the treatment of schizophrenia; Tiandixin used as an adjuvant therapy for malignant tumors, hydrothorax and ascites, and respiratory infections; Yitaida for acute promyelocytic leukemia and liver cancer; Lutingnuo, a glutathione injection for toxicity and injuries caused by ionizing radiation; and Beitangning, a pioglitazone hydrochloride capsule to control blood glucose. Further, it offers Nuosen for acute upper digestive tract hemorrhage; Sailimai for the treatment of diarrhea; Apleek Transdermal Patch for contraception; Sidinuo for osteoporosis; Glucosamine hydrochloride tablets for osteoarthritis; Oulai, a compound sodium aescinate gel for local swelling; Oukai for the treatment of soft tissue swelling and venous edema; and Fengshiye for patients who have pains in bones, joints, and limbs. The company distributes and sells pharmaceutical drugs; and manufactures and sells biopharmaceutical products. Luye Pharma Group Ltd. was founded in 1994 and is headquartered in Yantai, the People's Republic of China.

General Outlook

When we look at how much money they make before expenses, they keep 0.684% as profit. This shows they're good at controlling costs and are financially stable. Their operating profit, which is money made from regular business activities, is 0.144%. This means they run their business efficiently. Lastly, after paying all their bills, they still have a profit of 0.087%. This tells us they're good at keeping money after all costs.

Return on Investments

The company's asset efficiency, represented by a robust 0.021% return, is a testament to Luye Pharma Group Ltd.'s adeptness in optimizing resource deployment. Luye Pharma Group Ltd.'s utilization of its assets to generate profits is strikingly evident through a noteworthy return on equity of 0.045%. Furthermore, the proficiency of Luye Pharma Group Ltd. in capital utilization is underscored by a remarkable 0.051% return on capital employed.

Stock Prices

Luye Pharma Group Ltd.'s stock prices have been subject to undulating patterns. The peak stock value during this interval surged to $2.93, while its low point bottomed out at $2.81. This variance in figures offers investors a lucid insight into the roller-coaster ride that is Luye Pharma Group Ltd.'s stock market.

Liquidity Ratios

Analyzing 2186.HK liquidity ratios reveals its financial health of the firm. The current ratio of 131.53% gauges short-term asset coverage for liabilities. The quick ratio (133.66%) assesses immediate liquidity, while the cash ratio (69.49%) indicates cash reserves.

cards.indicatorcards.value
Current Ratio131.53%
Quick Ratio133.66%
Cash Ratio69.49%

Profitability Ratios

2186.HK profitability indicators offer a lens into its earnings landscape. A pretax profit margin of 11.40% underscores its earnings before tax deductions. The effective tax rate stands at 23.00%, revealing its tax efficiency. The net income per EBT, 76.08%, and the EBT per EBIT, 78.89%, provide insights into its earnings hierarchy. Lastly, with an EBIT per revenue ratio of 14.45%, we grasp its operational profitability.

cards.indicatorcards.value
Pretax Profit Margin11.40%
Effective Tax Rate23.00%
Net Income per EBT76.08%
EBT per EBIT78.89%
EBIT per Revenue14.45%

Operational Efficiency

Operational metrics shed light on its business agility. With an operating cycle of 1.32, it details the span from stock purchase to revenue. The 1 days it takes to settle debts showcases its creditor relations. Meanwhile, a 1 cash conversion cycle and 260.86% receivables turnover rate reflect its cash flow efficiency and credit management, respectively.

cards.indicatorcards.value
Days of Sales Outstanding134
Days of Inventory Outstanding156
Operating Cycle295.77
Days of Payables Outstanding144
Cash Conversion Cycle151
Receivables Turnover2.61
Payables Turnover2.53
Inventory Turnover2.34
Fixed Asset Turnover1.20
Asset Turnover0.24

Cash Flow Ratios

Peering into the cash flow metrics reveals liquidity and operational efficiency. The operating cash flow per share, 0.18, and free cash flow per share, 0.04, depict cash generation on a per-share basis. The cash per share value, 2.27, showcases liquidity position. Lastly, the operating cash flow sales ratio, 0.11, offers insight into cash flow relative to sales.

cards.indicatorcards.value
Operating Cash Flow per Share0.18
Free Cash Flow per Share0.04
Cash per Share2.27
Operating Cash Flow Sales Ratio0.11
Free Cash Flow to Operating Cash Flow Ratio0.21
Cash Flow Coverage Ratio0.08
Short Term Coverage Ratio0.13
Capital Expenditure Coverage Ratio1.27
Dividend Paid and Capex Coverage Ratio1.27

Debt and Leverage Ratios

Diving into debt and leverage metrics unveils the company's financial structure. The debt ratio, at 33.05%, highlights its total liabilities relative to assets. With a debt-equity ratio of 0.67, we discern the balance between debt and equity financing. The long-term debt to capitalization, 20.48%, and total debt to capitalization, 40.20%, ratios shed light on its capital structure. An interest coverage of 2.56 indicates its ability to manage interest expenses.

cards.indicatorcards.value
Debt Ratio33.05%
Debt Equity Ratio0.67
Long Term Debt to Capitalization20.48%
Total Debt to Capitalization40.20%
Interest Coverage2.56
Cash Flow to Debt Ratio0.08
Company Equity Multiplier2.03

Per Share Data

Speaking about the per share data offers a perceptive view of financial distribution. The revenue per share, 1.65, provides a glimpse into top-line earnings distributed across each share. Net income per share, 0.14, reflects the portion of profit attributed to each share. The book value per share, 3.36, represents the net asset value distributed per share, while the tangible book value per share, 1.65, excludes intangible assets.

cards.indicatorcards.value
Revenue Per Share1.65
Net Income Per Share0.14
Book Value Per Share3.36
Tangible Book Value Per Share1.65
Shareholders Equity Per Share3.36
Interest Debt Per Share2.44
Capex Per Share-0.31

Growth Ratios

Delving into growth metrics provides a snapshot of financial expansion. The revenue growth rate, 2.70%, indicates top-line expansion, while the gross profit growth, 1.54%, reveals profitability trends. EBIT growth, -26.96%, and operating income growth, -26.96%, offer insights into operational profitability progression. The net income growth, -11.94%, showcases bottom-line expansion, and the EPS growth, -17.65%, measures the growth in earnings per share.

cards.indicatorcards.value
Revenue Growth2.70%
Gross Profit Growth1.54%
EBIT Growth-26.96%
Operating Income Growth-26.96%
Net Income Growth-11.94%
EPS Growth-17.65%
EPS Diluted Growth-17.65%
Weighted Average Shares Growth7.11%
Weighted Average Shares Diluted Growth7.11%
Operating Cash Flow Growth-3.53%
Free Cash Flow Growth-12.22%
10-Year Revenue Growth per Share-67.72%
5-Year Revenue Growth per Share2.18%
3-Year Revenue Growth per Share-5.20%
10-Year Operating CF Growth per Share-51.92%
5-Year Operating CF Growth per Share31.31%
3-Year Operating CF Growth per Share31.98%
10-Year Net Income Growth per Share-77.33%
5-Year Net Income Growth per Share-64.84%
3-Year Net Income Growth per Share-35.56%
10-Year Shareholders Equity Growth per Share-6.38%
5-Year Shareholders Equity Growth per Share38.10%
3-Year Shareholders Equity Growth per Share35.75%
5-Year Dividend per Share Growth per Share-100.00%
3-Year Dividend per Share Growth per Share-100.00%
Receivables Growth32.02%
Inventory Growth7.11%
Asset Growth5.12%
Book Value per Share Growth14.97%
Debt Growth-7.48%
R&D Expense Growth-31.63%
SGA Expenses Growth12.39%

Other Metrics

Venturing into other key metrics unveils diverse facets of financial performance. The enterprise value, 15,370,088,547.655, captures the company's total value, considering both debt and equity. Income quality, 2.28, assesses the reliability of reported earnings. The sales, general, and administrative to revenue ratio, 0.10, gauges operational efficiency, while the research and development to revenue, 9.54%, highlights investment in innovation. The ratio of intangibles to total assets, 28.87%, indicates the value of non-physical assets, and capex to operating cash flow, -73.03%, measures reinvestment capability.

cards.indicatorcards.value
Enterprise Value15,370,088,547.655
Income Quality2.28
Sales General and Administrative to Revenue0.10
Research and Development to Revenue9.54%
Intangibles to Total Assets28.87%
Capex to Operating Cash Flow-73.03%
Capex to Revenue-18.97%
Capex to Depreciation-166.03%
Stock-Based Compensation to Revenue0.34%
Graham Number3.29
Return on Tangible Assets2.94%
Graham Net Net-0.34
Working Capital2,565,475,000
Tangible Asset Value6,168,684,000
Net Current Asset Value-1,258,939,000
Invested Capital1
Average Receivables2,069,292,500
Average Payables663,565,500
Average Inventory800,401,000
Days Sales Outstanding140
Days Payables Outstanding144
Days of Inventory On Hand156
ROIC3.26%
ROE0.04%

Valuation Ratios

Exploring the valuation ratios offers insights into perceived market value. The price to book value ratio, 0.83, and the price to book ratio, 0.83, reflect the market's valuation relative to the company's book value. The price to sales ratio, 1.69, provides a perspective on valuation in relation to sales. Ratios like price to free cash flows, 71.48, and price to operating cash flows, 15.08, gauge market valuation against cash flow metrics.

cards.indicatorcards.value
Price Book Value Ratio0.83
Price to Book Ratio0.83
Price to Sales Ratio1.69
Price Cash Flow Ratio15.08
Price Earnings to Growth Ratio1.80
Enterprise Value Multiple5.01
Price Fair Value0.83
Price to Operating Cash Flow Ratio15.08
Price to Free Cash Flows Ratio71.48
Price to Tangible Book Ratio1.01
Enterprise Value to Sales2.50
Enterprise Value Over EBITDA8.11
EV to Operating Cash Flow9.63
Earnings Yield4.23%
Free Cash Flow Yield3.41%
security
Trusted project
“All information displayed on the site is verified. High quality project and financial performance”
Eugene Alexeev
NumFin Founder and investing enthusiast

Frequently Asked Question

How many company shares are outstanding in 2024?

There are stock number shares outstanding of Luye Pharma Group Ltd. (2186.HK) on the HKSE in 2024.

What is P/E ratio of enterprise in 2024?

The current P/E ratio of enterprise is 19.531 in 2024.

What is the ticker symbol of Luye Pharma Group Ltd. stock?

The ticker symbol of Luye Pharma Group Ltd. stock is 2186.HK.

What is company IPO date?

IPO date of Luye Pharma Group Ltd. is 2014-07-09.

What is company current share price?

Current share price is 3.020 HKD.

What is stock market cap today?

The market cap of stock today is 11360243400.000.

What is PEG ratio in 2024?

The current 1.795 is 1.795 in 2024.

What is the number of employees in 2024?

In 2024 the company has 5005.